Schizophrenia/Psychosis

The extension trial aims to address the cognitive impairment often observed in schizophrenia.

Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

For the past 7 decades, there has only been 1 mechanism of action for schizophrenia treatment. Christoph Correll, MD, talks new options and cognitive impairment at the 2024 APA Annual Meeting.

This 2024 APA Annual Meeting poster estimated the prevalence of tardive dyskinesia in antipsychotic users in the US, and found rates ranging from 94.1-127.4 per 1000 antipsychotic users.

What makes this treatment option unique?

This interactive installation begs the question, “What is the truth of life with schizophrenia?”

The chief scientific officer and medical director of Segal Trials shares more on KarXT, a first in class for muscarinic agonists, and what he's excited about at the upcoming 2024 APA Annual Meeting.

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, discuss awareness among physicians of the concept of cognitive impairment associated with schizophrenia and detail unmet needs, including the lack of approved therapies, measurement tools, and access to cognitive remediation.

The new formulation was approved to help patients with tardive dyskinesia who have trouble swallowing.

The addition of 30 mg of evenamide to patients’ current antipsychotic medication was associated with a highly statistically significant reduction in the PANSS Total Score.

Here are some updates from the world of psychiatry throughout the month of April.

Two experts in the management of schizophrenia provide further insights on the disease pathophysiology, highlight the inflammatory impact on dendritic spines, and explore treatment considerations for this condition.

Here are highlights from the week in Psychiatric Times.

Compared with divided dosing, patients with once-daily dosing had shorter illness duration and better clinical outcomes.

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, provide clinical insights on the treatment of the three symptom domains of schizophrenia, highlighting their manifestations and treatments, including iclepertin.

Researchers investigated the effects of this supplementation on cognitive function and disease severity in schizophrenia. Here’s what they found.

Learn more about the latest data on KarXT, which is posed to be the first new pharmacological treatment for schizophrenia.

What is new in research on schizophrenia?

Here are some updates from the world of psychiatry throughout the month of March.

From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

The trial aims to investigate the positive, negative, and cognitive domains of schizophrenia.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

More than a gut feeling? Researchers investigated associations between the gut microbiome and treatment resistance in schizophrenia.

Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.

Check out this case study to learn more about how viral infections might play a role in triggering psychotic disorders.